Target RWE at ISPOR 2025
Learn about our activity and RWE solutions at the ISPOR annual congress
Explore our Real-World Data & Insights
Target RWE is excited to participate in the ISPOR Annual Congress 2025, taking place from May 13–16 in Montreal, Canada. We look forward to engaging with industry leaders, exploring the latest advancements in research, and supporting our Chief Scientific Officer, Jennifer Christian, PharmD, PhD, FISPE, who will be speaking at the conference. It’s an exciting time to see how research is advancing, and we can’t wait to be part of the conversation and contribute to the ongoing dialogue at ISPOR.
Leadership and Expertise at ISPOR
Notable Achievements
- Expansion of Real-World Data Capabilities: Contributed to over 35 research publications, abstract posters, and oral presentations, focusing on disease areas with high unmet medical needs.
- Setting New Epidemiology & Statistics Standards in RWE: Delivered 10 abstract posters and oral presentations showcasing advanced RWE methodologies at major conferences, reinforcing our leadership in the field.
Past Presentations at ISPOR 2024
Assessing unmeasured confounding using negative control outcomes
This poster explored the use of negative control outcomes (NCOs) as a tool to assess unmeasured confounding in observational studies. By understanding how NCOs can reveal potential biases, researchers can improve the validity of real-world evidence. Dive into the full poster to learn how this methodology strengthens our ability to draw stronger conclusions from complex data.
Learn More
Patient Cloning for Assessing Dynamic Treatment Protocols: A Novel Approach for Observational Data Analysis Using Real-World Data (RWD).
This poster introduced a novel "patient cloning" approach to analyzing real-world data, enabling the evaluation of dynamic treatment protocols that adapt to changing patient conditions over time. Unlike traditional methods, this technique allows for the assessment of complex treatment sequences. Explore the full poster to understand how this innovative methodology can provide deeper insights into optimal disease management.
Learn More
Addressing RWE Challenges in Real-Time: The ‘Clean Room Committee’ Approach
This poster detailed Target RWE's innovative "Clean Room Committee" approach, designed to address real-world evidence (RWE) challenges in real-time while mitigating investigator bias. Discover how this unique methodology ensures the integrity of regulatory-grade studies through a structured, independent review process. Dive into the full poster to explore the staged approach and its application in a case study on preoperative cefazolin safety.
Learn More2024 Research Presentation Videos
Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study
This video features a Target RWE study presented at ISPE 2024, "Comparing causal estimands from a sequential nested trial emulation with a treatment decision design to a conventional single point randomized trial: A simulation study." Authored by Kathleen Hurwitz, ScD, Catherine Wiener, and Chase Latour, this presentation offers valuable insights into the use of sequential nested trial emulations, particularly within rare disease research. Explore how careful study design and analysis can ensure accurate and impactful results.
Making the Case for Negative Control Outcome Studies in a Real-World Evidence Setting.
Target RWE Director of Data Management & Statistics, David Pritchard, PhD, provided an insightful video preview of his presentation at the DIA Real-World Evidence (RWE) Conference titled 'Making the Case for Negative Control Outcome Studies in a Real-World Evidence Setting.' In this session, Dr. Pritchard delved into using Negative Control Outcome studies (NCOs) as a methodological approach to ensure robust treatment group comparability, ultimately strengthening study validity and reliability in real-world research settings. Watch the video to gain a deeper understanding of how NCO studies can enhance the accuracy of your research, reduce bias, and elevate the overall quality of your study findings.
Seeing Eye to Eye: Enhancing Inter-Team Communication for Reproducible Real-World Evidence
In this video, Nuvan Rathnayaka, Manager of Biostatistics at Target RWE, shared insights into this innovative approach and explains how effective communication frameworks can lead to more accurate real-world data analysis. Click the link to watch the video to learn more about the research, titled "Seeing Eye to Eye: Enhancing Inter-Team Communication for Reproducible Real-World Evidence."
Data Agnostic, Insight Driven: Elevating Observational Research with Robust Methodologies
Discover how Target RWE's data-agnostic tools and expertise in modern epidemiological methods and statistical rigor are foundational to maximizing observational clinical research. Our ability to utilize diverse data sources, from claims to curated electronic health records, ensures scientific integrity and streamlined multi-source studies. With a collaborative approach and advanced analytics, including comprehensive study design consulting, we empower our partners to gain cohesive, high-quality data insights, meeting even the most complex research needs.
causalStudio™: Advancing Accessibility of Causal Inference for Real-World Data Analysis
causalRisk™ provides a collection of validated statistical routines that estimate the cumulative risk of a right-censored counterfactual outcome that may be subject to dependent right censoring, confounding, selection bias, and competing risks. These routines are verified by a suite of automated tests that compare the results produced by the package to those calculated by creating special cases of the estimators for a given situation using only standard R packages.
The causalPHR™ platform supports the easy creation of crucial information for supporting epidemiological studies such as descriptive tables of study populations, cumulative incidence and survival curves for safety or adverse events, and Sankey and sunburst figures for describing treatment patterns, among many other types of visual displays. Additional valuable features for supporting project workflows include integrated commenting among collaborators, project versioning facilities, and selective access controls for partners.
causalRisk™ has been used to support submissions to various regulatory agencies including the FDA, Chinese FDA, and Health Canada.
